An overview of imidazole and its analogues as potent anticancer agents

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov. Today 13(1–2), 30–37 (2008).
  Medline CASGoogle Scholar
• 2. Ali I, Lone MN, Aboul-Enein HY. Imidazoles as potential anticancer agents. MedChemComm 8(9), 1742–1773 (2017). • Defines the role of imdazole and fused imidazole anaologues as potential anticancer agents.
  Medline CASGoogle Scholar
• 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
  MedlineGoogle Scholar
• 4. Ferlay J, Ervik M, Lam F et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, Lyon, France (2020). https://gco.iarc.fr/today • Gives a statistical analysis of deaths occurring due to cancer and future statistics related to cancer deaths.
  Google Scholar
• 5. Tsimberidou A-M. Targeted therapy in cancer. Cancer Chemother. Pharmacol. 76(6), 1113–1132 (2015).
  Medline CASGoogle Scholar
• 6. Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J. Exp. Clin. Cancer Res. 38(1), 156 (2019).
  Medline CASGoogle Scholar
• 7. Rana A, Alex J, Chauhan M, Joshi G, Kumar R. A review on pharmacophoric designs of antiproliferative agents. Med. Chem. Res. 24, 903–920 (2014).
  Google Scholar
• 8. Vitaku E, Smith DT, Njardarson JT. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals: miniperspective. J. Med. Chem. 57(24), 10257–10274 (2014).
  Medline CASGoogle Scholar
• 9. Vitaku E, Smith DT, Njardarson JT. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J. Med. Chem. 57(24), 10257–10274 (2014).
  Medline CASGoogle Scholar
• 10. Li X-L, Hu Y-J, Wang H, Yu B-Q, Yue H-L. Molecular spectroscopy evidence of berberine binding to DNA: comparative binding and thermodynamic profile of intercalation. Biomacromolecules 13(3), 873–880 (2012).
  Medline CASGoogle Scholar
• 11. Alniss HY, Anthony NG, Khalaf AI et al. Rationalising sequence selection by ligand assemblies in the DNA minor groove: the case for thiazotropsin A. Chem. Sci. 3(3), 711–722 (2012).
  CASGoogle Scholar
• 12. Ketron AC, Denny WA, Graves DE, Osheroff N. Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions. Biochemistry 51(8), 1730–1739 (2012).
  Medline CASGoogle Scholar
• 13. Świderski G, Łaźny R, Sienkiewicz M et al. Synthesis, spectroscopic, and theoretical study of copper and cobalt complexes with dacarbazine. Materials (Basel) 14(12), 12 (2021).
  Google Scholar
• 14. Groessl M, Reisner E, Hartinger CG et al. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity. J. Med. Chem. 50(9), 2185–2193 (2007).
  Medline CASGoogle Scholar
• 15. Zhang L, Peng X, Damu GLV, Geng R, Zhou C. Comprehensive review in current developments of imidazole-based medicinal chemistry. Med. Res. Rev. 34(2), 340–437 (2014).
  MedlineGoogle Scholar
• 16. Sharma P, Larosa C, Antwi J, Govindarajan R, Werbovetz KA. Imidazoles as potential anticancer agents: an update on recent studies. Molecules 26(14), 4213 (2021).
  Medline CASGoogle Scholar
• 17. Molina P, Tárraga A, Otón F. Imidazole derivatives: a comprehensive survey of their recognition properties. Org. Biomol. Chem. 10(9), 1711–1724 (2012).
  Medline CASGoogle Scholar
• 18. Kanawaade P, Sharma N, Pandhare R, Kanawade MP. A review on: imidazole derivatives as a multifunctional moiety. Eur. J. Mol. Clin. Med. 10(01), 4382–4405 (2023).
  Google Scholar
• 19. Aleksandrova EV, Kravchenko AN, Kochergin PM. Properties of haloimidazoles (review). Chem. Heterocycl. Compd 47(3), 261 (2011).
  CASGoogle Scholar
• 20. Narasimhan B, Sharma D, Kumar P. Biological importance of imidazole nucleus in the new millennium. Med. Chem. Res. 20, 1119–1140 (2010).
  Google Scholar
• 21. Boiani M, González M. Imidazole and benzimidazole derivatives as chemotherapeutic agents. Mini Rev. Med. Chem. 5(4), 409–424 (2005).
  Medline CASGoogle Scholar
• 22. Tolomeu HV, Fraga CAM. Imidazole: synthesis, functionalization and physicochemical properties of a privileged structure in medicinal chemistry. Molecules 28(2), 838 (2023).
  Medline CASGoogle Scholar
• 23. Debus H. Ueber die einwirkung des ammoniaks auf glyoxal. Eur. J. Org. Chem. 107(2), 199–208 (1858).
  Google Scholar
• 24. Zheng X, Ma Z, Zhang D. Synthesis of imidazole-based medicinal molecules utilizing the van leusen imidazole synthesis. Pharmaceuticals 13(3), 37 (2020).
  Medline CASGoogle Scholar
• 25. Akritopoulou-Zanze I. Isocyanide-based multicomponent reactions in drug discovery. Curr. Opin. Chem. Biol. 12(3), 324–331 (2008).
  Medline CASGoogle Scholar
• 26. Lujan-Montelongo JA, Estevez AO, Fleming FF. Alkyl sulfinates: formal nucleophiles for synthesizing TosMIC analogs. Eur. J. Org. Chem. 2015(7), 1602–1605 (2015).
  Medline CASGoogle Scholar
• 27. Mathiyazhagan AD, Anilkumar G. Recent advances and applications of p-toluenesulfonylmethyl isocyanide (TosMIC). Org. Biomol. Chem. 17(28), 6735–6747 (2019).
  Medline CASGoogle Scholar
• 28. Zhang C, Moran EJ, Woiwode TF, Short KM, Mjalli AMM. Synthesis of tetrasubstituted imidazoles via α-(N-acyl-N-alkylamino)-β-ketoamides on Wang resin. Tetrahedron Lett. 37(6), 751–754 (1996).
  CASGoogle Scholar
• 29. Balalaie S, Hashemi M, Akhbari M. A novel one-pot synthesis of tetrasubstituted imidazoles under solvent-free conditions and microwave irradiation. Tetrahedron Lett. 44, 1709–1711 (2003).
  CASGoogle Scholar
• 30. Wolkenberg SE, Wisnoski DD, Leister WH, Wang Y, Zhao Z, Lindsley CW. Efficient synthesis of imidazoles from aldehydes and 1,2-diketones using microwave irradiation. Org. Lett. 6(9), 1453–1456 (2004).
  Medline CASGoogle Scholar
• 31. Vorbrüggen H, Krolikiewicz K. A simple synthesis of Δ2-oxazolines, Δ2-oxazines, Δ2-thiazolines and Δ2-imidazolines. Tetrahedron Lett. 22(45), 4471–4474 (1981).
  CASGoogle Scholar
• 32. Pathan M, Paike V, Pachmase P, More S, Ardhapure S, Pawar R. Microwave-assisted facile synthesis of 2-substituted 2-imidazolines. Ark. Arch. Org. Chem. 2006(15), 205–210 (2006).
  Google Scholar
• 33. Sharma AK. A convenient approach for the synthesis of imidazole derivatives using microwaves. Der. Pharm. Lett. 6(3), 431–447 (2012).
  Google Scholar
• 34. Chakravarthi BVSK, Pathi SS, Goswami MT et al. The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget 5(16), 6654–6669 (2014).
  MedlineGoogle Scholar
• 35. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem. Rev. 109(7), 3012–3043 (2009).
  Medline CASGoogle Scholar
• 36. Peng X-M, Damu GLV, Zhou C. Current developments of coumarin compounds in medicinal chemistry. Curr. Pharm. Des. 19, 3884–3930 (2013).
  Medline CASGoogle Scholar
• 37. Montaseri H, Kruger CA, Abrahamse H. Recent advances in porphyrin-based inorganic nanoparticles for cancer treatment. Int. J. Mol. Sci. 21(9), 3358 (2020).
  Medline CASGoogle Scholar
• 38. Bae SH, Park JH, Choi HG, Kim H, Kim SH. Imidazole antifungal drugs inhibit the cell proliferation and invasion of human breast cancer cells. Biomol. Ther. (Seoul) 26(5), 494–502 (2018).
  Medline CASGoogle Scholar
• 39. Parker AL, Kavallaris M, McCarroll JA. Microtubules and their role in cellular stress in cancer. Front. Oncol. 4, 153 (2014). •• Provides information related to microtubules, which are important pillars for cell activity, and their alteration's impact on cellular functions; therefore, they are one the most important targets for cancer treatment.
  MedlineGoogle Scholar
• 40. Florian S, Mitchison TJ. Anti-microtubule drugs. Mitotic Spindl. Methods Protoc. 1413, 403–421 (2016).
  CASGoogle Scholar
• 41. Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm. Res. 29(11), 2943–2971 (2012).
  Medline CASGoogle Scholar
• 42. Shan Y, Zhang J, Liu Z, Wang M, Dong Y. Developments of combretastatin A-4 derivatives as anticancer agents. Curr. Med. Chem. 18(4), 523–538 (2011).
  Medline CASGoogle Scholar
• 43. Chaudhary A, Pandeya SN, Kumar P et al. Combretastatin a-4 analogs as anticancer agents. Mini Rev. Med. Chem. 7(12), 1186–1205 (2007).
  Medline CASGoogle Scholar
• 44. Lu Y, Li C-M, Wang Z et al. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J. Med. Chem. 52(6), 1701–1711 (2009).
  Medline CASGoogle Scholar
• 45. Romagnoli R, Baraldi PG, Cruz-Lopez O et al. Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues. J. Med. Chem. 53(10), 4248–4258 (2010).
  Medline CASGoogle Scholar
• 46. Beale TM, Myers RM, Shearman JW et al. Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4. MedChemCommun 1(3), 202–208 (2010).
  CASGoogle Scholar
• 47. Biersack B, Muthukumar Y, Schobert R, Sasse F. Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles. Bioorg. Med. Chem. Lett. 21(21), 6270–6273 (2011).
  Medline CASGoogle Scholar
• 48. Rahimzadeh Oskuei S, Mirzaei S, Reza Jafari-Nik M et al. Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors. Bioorg. Chem. 112, doi: 10.1016/j.bioorg.2021.104904 (2021).
  Google Scholar
• 49. Lindel T, Jensen PR, Fenical W et al. Eleutherobin, a new cytotoxin that mimics paclitaxel (taxol) by stabilizing microtubules. J. Am. Chem. Soc. 119(37), 8744–8745 (1997).
  CASGoogle Scholar
• 50. Long BH, Carboni JM, Wasserman AJ et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res. 58(6), 1111–1115 (1998).
  Medline CASGoogle Scholar
• 51. Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 38(17), 5490–5498 (1999).
  Medline CASGoogle Scholar
• 52. Nicolaou KC, van Delft F, Ohshima T et al. Total synthesis of eleutherobin. Angew. Chemie Int. Ed. Engl. 36(22), 2520–2524 (1997).
  CASGoogle Scholar
• 53. Nicolaou KC, Kim S, Pfefferkorn J et al. Synthesis and biological activity of sarcodictyins. Angew. Chemie Int. Ed. 37(10), 1418–1421 (1998).
  Medline CASGoogle Scholar
• 54. LaBarbera DV, Modzelewska K, Glazar AI et al. The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anticancer Drugs 20(6), 425–436 (2009).
  Medline CASGoogle Scholar
• 55. Bielawski K, Bielawska A, Poplawska B. Synthesis and cytotoxic activity of novel amidine analogues of bis(2-chloroethyl)amine. Arch. Pharm. (Weinheim) 342(8), 484–490 (2009).
  Medline CASGoogle Scholar
• 56. Li W-T, Hwang D-R, Song J-S et al. Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents. Invest. New Drugs 30(1), 164–175 (2012).
  MedlineGoogle Scholar
• 57. Li L, Quan D, Chen J et al. Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents. Eur. J. Med. Chem. 184, doi:10.1016/j.ejmech.2019.111732 (2019) (Epub ahead of print).
  Google Scholar
• 58. Wang Q, Arnst KE, Wang Y et al. Structural modification of the 3,4,5-trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved antiproliferative activities. J. Med. Chem. 61(17), 7877–7891 (2018).
  Medline CASGoogle Scholar
• 59. Wang Q, Arnst KE, Wang Y et al. Structure-guided design, synthesis, and biological evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) methanone (ABI-231) analogues targeting the colchicine binding site in tubulin. J. Med. Chem. 62(14), 6734–6750 (2019).
  Medline CASGoogle Scholar
• 60. Bai Z, Liu X, Guan Q et al. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells. Chem. Biol. Interact. 315, doi:10.1016/j.cbi.2019.108886 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 61. Sayeed IB, Vishnuvardhan MVPS, Nagarajan A, Kantevari S, Kamal A. Imidazopyridine linked triazoles as tubulin inhibitors, effectively triggering apoptosis in lung cancer cell line. Bioorg. Chem. 80, 714–720 (2018).
  Medline CASGoogle Scholar
• 62. Mullagiri K, Nayak VL, Sunkari S et al. New (3-(1H-benzo[d]imidazol-2-yl))/(3-(3H-imidazo[4,5-b]pyridin-2-yl))-(1H-indol-5-yl)(3,4,5-trimethoxyphenyl)methanone conjugates as tubulin polymerization inhibitors. MedChemComm 9(2), 275–281 (2018).
  Medline CASGoogle Scholar
• 63. Narasimha Rao MP, Nagaraju B, Kovvuri J et al. Synthesis of imidazo-thiadiazole linked indolinone conjugates and evaluated their microtubule network disrupting and apoptosis inducing ability. Bioorg. Chem. 76, 420–436 (2018).
  MedlineGoogle Scholar
• 64. Baig MF, Nayak VL, Budaganaboyina P et al. Synthesis and biological evaluation of imidazo[2,1-b]thiazole-benzimidazole conjugates as microtubule-targeting agents. Bioorg. Chem. 77, 515–526 (2018).
  Medline CASGoogle Scholar
• 65. Donthiboina K, Anchi P, Gurram S et al. Synthesis and biological evaluation of substituted N-(2-(1H-benzo[d]imidazol-2-yl)phenyl)cinnamides as tubulin polymerization inhibitors. Bioorg. Chem. 103, doi:10.1016/j.bioorg.2020.104191 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 66. Wang Y-T, Shi T-Q, Zhu H-L, Liu C-H. Synthesis, biological evaluation and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors. Bioorg. Med. Chem. 27(3), 502–515 (2019).
  Medline CASGoogle Scholar
• 67. Zhang Q, Hu X, Wan G et al. Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer. Eur. J. Med. Chem. 184, doi:10.1016/j.ejmech.2019.111728 (2019) (Epub ahead of print).
  Google Scholar
• 68. Hu X, Li L, Zhang Q et al. Design, synthesis and biological evaluation of a novel tubulin inhibitor SKLB0565 targeting the colchicine binding site. Bioorg. Chem. 97, doi:10.1016/j.bioorg.2020.103695 (2020) (Epub ahead of print).
  Google Scholar
• 69. Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol. Ther. 151, 141–151 (2015).
  Medline CASGoogle Scholar
• 70. Huang P, Le X, Huang F et al. Discovery of a dual tubulin polymerization and cell division cycle 20 homologue inhibitor via structural modification on apcin. J. Med. Chem. 63(9), 4685–4700 (2020).
  Medline CASGoogle Scholar
• 71. Coussens L, Parker PJ, Rhee L et al. Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. Science 233(4766), 859–866 (1986).
  Medline CASGoogle Scholar
• 72. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 298(5600), 1912–1934 (2002).
  Medline CASGoogle Scholar
• 73. Bhullar KS, Lagarón NO, McGowan EM et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol. Cancer 17(1), 48 (2018). •• The work focuses on kinases that are crucial to cancer carcinogenesis and metastasis as shown by recent advances in our understanding of cancer cell signaling pathways.
  MedlineGoogle Scholar
• 74. Bardelli A, Parsons DW, Silliman N et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300(5621), 949 (2003).
  Medline CASGoogle Scholar
• 75. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15(6), 385–403 (2016).
  Medline CASGoogle Scholar
• 76. Gerber H-P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65(3), 671–680 (2005).
  Medline CASGoogle Scholar
• 77. Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat. Rev. Clin. Oncol. 9(9), 498–509 (2012).
  Medline CASGoogle Scholar
• 78. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61(3), 253–270 (2001).
  Medline CASGoogle Scholar
• 79. Yadav L, Puri N, Rastogi V, Satpute P, Sharma V. Tumour angiogenesis and angiogenic inhibitors: a review. J. Clin. Diagn. Res. 9(6), XE01–XE05 (2015).
  MedlineGoogle Scholar
• 80. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J. Surg. Res. 67(2), 147–154 (1997).
  Medline CASGoogle Scholar
• 81. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2(12), 1097–1105 (2011).
  MedlineGoogle Scholar
• 82. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling–in control of vascular function. Nat. Rev. Mol. Cell Biol. 7(5), 359–371 (2006).
  Medline CASGoogle Scholar
• 83. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114(Pt 5), 853–865 (2001).
  Medline CASGoogle Scholar
• 84. Sisko JT, Tucker TJ, Bilodeau MT et al. Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. Bioorg. Med. Chem. Lett. 16(5), 1146–1150 (2006).
  Medline CASGoogle Scholar
• 85. Wang C, Gao H, Dong J et al. Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: design, synthesis and biological evaluation. Bioorg. Med. Chem. 22(1), 277–284 (2014).
  MedlineGoogle Scholar
• 86. Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 17(10), 611–625 (2016).
  Medline CASGoogle Scholar
• 87. Mostafa AS, Gomaa RM, Elmorsy MA. Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR-2 inhibitors with anti-breast cancer activity. Chem. Biol. Drug Des. 93(4), 454–463 (2019).
  Medline CASGoogle Scholar
• 88. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 17(3), 259–269 (1999).
  Medline CASGoogle Scholar
• 89. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol. Oncol. 12(1), 3–20 (2018).
  MedlineGoogle Scholar
• 90. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19(3), 183–232 (1995).
  Medline CASGoogle Scholar
• 91. Schlessinger J. Receptor tyrosine kinases: legacy of the first two decades. Cold Spring Harb. Perspect. Biol. 6(3), a008912 (2014).
  MedlineGoogle Scholar
• 92. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12(8), 553–563 (2012).
  Medline CASGoogle Scholar
• 93. Akhtar MJ, Khan AA, Ali Z et al. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors. Bioorg. Chem. 78, 158–169 (2018).
  Medline CASGoogle Scholar
• 94. Hickinson DM, Klinowska T, Speake G et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res. 16(4), 1159–1169 (2010).
  Medline CASGoogle Scholar
• 95. Amin KM, Barsoum FF, Awadallah FM, Mohamed NE. Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity. Eur. J. Med. Chem. 123, 191–201 (2016).
  Medline CASGoogle Scholar
• 96. Hei Y-Y, Shen Y, Wang J et al. Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors. Bioorg. Med. Chem. 26(8), 2173–2185 (2018).
  Medline CASGoogle Scholar
• 97. Lei H, Fan S, Zhang H et al. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. Eur. J. Med. Chem. 186, doi:10.1016/j.ejmech.2019.111888 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 98. Abou-Zied HA, Youssif BGM, Mohamed MFA, Hayallah AM, Abdel-Aziz M. EGFR inhibitors and apoptotic inducers: design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules. Bioorg. Chem. 89, doi:10.1016/j.bioorg.2019.102997 (2019).
  MedlineGoogle Scholar
• 99. Mitupatum T, Aree K, Kittisenachai S et al. mRNA expression of Bax, Bcl-2, p53, cathepsin B, caspase-3 and caspase-9 in the HepG2 cell line following induction by a novel monoclonal Ab Hep88 mAb: cross-talk for paraptosis and apoptosis. Asian Pac. J. Cancer Prev. 17(2), 703–712 (2016).
  MedlineGoogle Scholar
• 100. Hisham M, Youssif BGM, Osman EEA, Hayallah AM, Abdel-Aziz M. Synthesis and biological evaluation of novel xanthine derivatives as potential apoptotic antitumor agents. Eur. J. Med. Chem. 176, 117–128 (2019).
  Medline CASGoogle Scholar
• 101. Srour AM, Ahmed NS, Abd El-Karim SS, Anwar MM, El-Hallouty SM. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors. Bioorg. Med. Chem. 28(18), doi:10.1016/j.bmc.2020.115657 (2020).
  MedlineGoogle Scholar
• 102. Moerkens M, Zhang Y, Wester L, van de Water B, Meerman JHN. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation. BMC Cancer 14(1), 283 (2014).
  MedlineGoogle Scholar
• 103. Nunes-Xavier CE, Elson A, Pulido R. Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells. J. Biol. Chem. 287(5), 3433–3444 (2012).
  Medline CASGoogle Scholar
• 104. Amin KM, Syam YM, Anwar MM, Ali HI, Abdel-Ghani TM, Serry AM. Synthesis and molecular docking study of new benzofuran and furo[3,2-g]chromone-based cytotoxic agents against breast cancer and p38α MAP kinase inhibitors. Bioorg. Chem. 76, 487–500 (2018).
  Medline CASGoogle Scholar
• 105. Hosamani KM, Reddy DS, Devarajegowda HC. Microwave-assisted synthesis of new fluorinated coumarin–pyrimidine hybrids as potent anticancer agents{,} their DNA cleavage and x-ray crystal studies. RSC Adv. 5(15), 11261–11271 (2015).
  CASGoogle Scholar
• 106. Luo G, Tang Z, Lao K, Li X, You Q, Xiang H. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity. Eur. J. Med. Chem. 150, 783–795 (2018).
  Medline CASGoogle Scholar
• 107. Nossier ES, El-hallouty SM, Zaki ER. Synthesis, anticancer evaluation and molecular modeling of some substituted thiazolidinonyl and thiazolyl pyrazole derivatives. Int. J. Pharm. Pharm. Sci. 7(11), 353–359 (2015).
  CASGoogle Scholar
• 108. Abbas H-AS, Abd El-Karim SS. Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents. Bioorg. Chem. 89, doi:10.1016/j.bioorg.2019.103035 (2019) (Epub ahead of print).
  MedlineGoogle Scholar
• 109. Syam YM, Anwar MM, Kotb ER, Elseginy SA, Awad HM, Awad GEA. Development of promising thiopyrimidine-based anti-cancer and antimicrobial agents: synthesis and QSAR analysis. Mini Rev. Med. Chem. 19(15), 1255–1275 (2019).
  Medline CASGoogle Scholar
• 110. Kalra S, Joshi G, Kumar M et al. Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition. RSC Med. Chem. 11(8), 923–939 (2020).
  Medline CASGoogle Scholar
• 111. Sawant DM, Sharma S, Pathare RS et al. Relay tricyclic Pd(ii)/Ag(i) catalysis: design of a four-component reaction driven by nitrene-transfer on isocyanide yields inhibitors of EGFR. Chem. Commun. 54(82), 11530–11533 (2018).
  Medline CASGoogle Scholar
• 112. Chauhan M, Joshi G, Kler H et al. Dual inhibitors of epidermal growth factor receptor and topoisomerase IIα derived from a quinoline scaffold. RSC Adv. 6(81), 77717–77734 (2016).
  CASGoogle Scholar
• 113. Joshi G, Nayyar H, Kalra S et al. Pyrimidine containing epidermal growth factor receptor kinase inhibitors: synthesis and biological evaluation. Chem. Biol. Drug Des. 90(5), 995–1006 (2017).
  Medline CASGoogle Scholar
• 114. Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13(4), 397–411 (1911).
  Medline CASGoogle Scholar
• 115. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim. Biophys. Acta 1287(2–3), 121–149 (1996).
  MedlineGoogle Scholar
• 116. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13, 513–609 (1997).
  Medline CASGoogle Scholar
• 117. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am. J. Hematol. 89(5), 547–556 (2014).
  Medline CASGoogle Scholar
• 118. Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36(7), 422–439 (2015).
  Medline CASGoogle Scholar
• 119. Hassan AQ, Sharma SV, Warmuth M. Allosteric inhibition of BCR-ABL. Cell Cycle 9(18), 3710–3714 (2010).
  Medline CASGoogle Scholar
• 120. Roskoski RJ. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol. Res. 94, 9–25 (2015).
  Medline CASGoogle Scholar
• 121. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9(1), 28–39 (2009).
  MedlineGoogle Scholar
• 122. Francini CM, Fallacara AL, Artusi R et al. Identification of aminoimidazole and aminothiazole derivatives as Src family kinase inhibitors. ChemMedChem 10(12), 2027–2041 (2015).
  Medline CASGoogle Scholar
• 123. Bertrand J, Dostálová H, Krystof V et al. New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia. Bioorg. Chem. 94, doi:10.1016/j.bioorg.2019.103361 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 124. Liang C, Tian D, Ren X et al. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur. J. Med. Chem. 151, 315–326 (2018).
  Medline CASGoogle Scholar
• 125. Desogus A, Schenone S, Brullo C, Tintori C, Musumeci F. Bcr-Abl tyrosine kinase inhibitors: a patent review. Expert Opin. Ther. Pat. 25(4), 397–412 (2015).
  Medline CASGoogle Scholar
• 126. Calderón-Arancibia J, Espinosa-Bustos C, Cañete-Molina Á et al. Synthesis and pharmacophore modelling of 2,6,9-trisubstituted purine derivatives and their potential role as apoptosis-inducing agents in cancer cell lines. Molecules 20(4), 6808–6826 (2015).
  Medline CASGoogle Scholar
• 127. Gucký T, Řezníčková E, Radošová Muchová T et al. Discovery of N(2)-(4-Amino-cyclohexyl)-9-cyclopentyl- N(6)-(4-morpholin-4-ylmethyl-phenyl)- 9H-purine-2,6-diamine as a potent FLT3 kinase inhibitor for acute myeloid leukemia with FLT3 mutations. J. Med. Chem. 61(9), 3855–3869 (2018).
  Medline CASGoogle Scholar
• 128. Lorz PM, Towae FK, Enke W, Jäckh R, Bhargava N, Hillesheim W. Phthalic acid and derivatives. Ullmann's Encycl. Ind. Chem. doi:10.1002/14356007.a20_181 (2000).
  Google Scholar
• 129. Storrie B, Madden EA. Buffer for assay of horseradish peroxidase meth. Enzymologia 182, 217 (1990).
  Google Scholar
• 130. Nishie K, Waiss AC Jr, Keyl AC. Toxicity of methylimidazoles. Toxicol. Appl. Pharmacol. 14(2), 301–307 (1969).
  Medline CASGoogle Scholar
• 131. Shalini K, Sharma PK, Kumar N. Imidazole and its biological activities: a review. Der Chem. Sin. 1(3), 36–47 (2010).
  CASGoogle Scholar
• 132. Chan PC, Hill GD, Kissling GE, Nyska A. Toxicity and carcinogenicity studies of 4-methylimidazole in F344/N rats and B6C3F1 mice. Arch. Toxicol. 82(1), 45–53 (2008).
  Medline CASGoogle Scholar
• 133. Uçucu Ü, Karaburun NG, Işikdağ İ. Synthesis and analgesic activity of some 1-benzyl-2-substituted-4, 5-diphenyl-1H-imidazole derivatives. Farmaco Sci. 56(4), 285–290 (2001).
  CASGoogle Scholar
• 134. Al-Azzawi RW. Evaluation of some properties of three types of denture reline materials with miconazole (antifungal agent) preparation. Master's Thesis, Prosthet. Dep. Univ. Baghdad (2007) (Online).
  Google Scholar
• 135. Ebeol K, Koehler H, Gamer AO, Jackh R. Imidazole and derivatives. Ullmann's Encycl. Ind. Chem. Wiley 18, 637–645 (2000).
  Google Scholar
• 136. Chen H-L, Kao H-F, Wang J-Y, Wei G-T. Cytotoxicity of imidazole ionic liquids in human lung carcinoma A549 cell line. J. Chinese Chem. Soc. 61(7), 763–769 (2014). •• Toxicity is a major issue hindering the development of new drugs, therefore, a clear idea about toxicity concerns is important, as provided in this study.
  CASGoogle Scholar
• 137. Nørregaard A, Jensen SS, Kolenda J et al. Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers. Neurotox. Res. 22(1), 43–58 (2012).
  Medline CASGoogle Scholar
• 138. Singh K, Verma V, Yadav K et al. Design, regioselective synthesis and cytotoxic evaluation of 2-aminoimidazole-quinoline hybrids against cancer and primary endothelial cells. Eur. J. Med. Chem. 87, 150–158 (2014).
  Medline CASGoogle Scholar
• 139. Nepali K, Lee H-Y, Liou J-P. Nitro-group-containing drugs. J. Med. Chem. 62(6), 2851–2893 (2018).
  MedlineGoogle Scholar
• 140. Patterson S, Wyllie S, Norval S et al. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. Elife 5, e09744 (2016).
  MedlineGoogle Scholar
• 141. Landge S, Ramachandran V, Kumar A et al. Nitroarenes as antitubercular agents: stereoelectronic modulation to mitigate mutagenicity. ChemMedChem 11(3), 331–339 (2016).
  Medline CASGoogle Scholar
• 142. Boechat N, Carvalho AS, Salomão K et al. Studies of genotoxicity and mutagenicity of nitroimidazoles: demystifying this critical relationship with the nitro group. Mem. Inst. Oswaldo Cruz 110, 492–499 (2015).
  Medline CASGoogle Scholar
• 143. Rojo G, Castillo C, Duaso J et al. Toxic and therapeutic effects of nifurtimox and benznidazol on Trypanosoma cruzi ex vivo infection of human placental chorionic villi explants. Acta Trop. 132, 112–118 (2014).
  Medline CASGoogle Scholar
• 144. Wilkinson SR, Bot C, Kelly JM, Hall BS. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr. Top. Med. Chem. 11(16), 2072–2084 (2011).
  Medline CASGoogle Scholar
• 145. Alirol E, Schrumpf D, Amici Heradi J et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. Clin. Infect. Dis. 56(2), 195–203 (2013).
  Medline CASGoogle Scholar
• 146. Davies C, Dey N, Negrette OS, Parada LA, Basombrio MA, Garg NJ. Hepatotoxicity in mice of a novel anti-parasite drug candidate hydroxymethylnitrofurazone: a comparison with benznidazole. PLOS Negl. Trop. Dis. 8(10), e3231 (2014).
  MedlineGoogle Scholar
• 147. Minsky BD, Leibel SA. The treatment of hepatic metastases from colorectal cancer with radiation therapy alone or combined with chemotherapy or misonidazole. Cancer treatment reviews 16(4), 213–9 (1989).
  Medline CASGoogle Scholar
• 148. Bahia MT, Andrade IM, Martins TA et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLOS neglected tropical diseases 6(11), e1870 (2012).
  Medline CASGoogle Scholar
• 149. Bleehen NM, Maughan TS, Workman P, Newman HF, Stenning S, Ward R. The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study. Radiother. Oncol. 20, 137–142 (1991).
  MedlineGoogle Scholar
• 150. Carvalho AS, Salomão K, Castro SL et al. Megazol and its bioisostere 4H-1, 2, 4-triazole: comparing the trypanocidal, cytotoxic and genotoxic activities and their in vitro and in silico interactions with the Trypanosoma brucei nitroreductase enzyme. Mem. Inst. Oswaldo Cruz 109, 315–323 (2014).
  MedlineGoogle Scholar
• 151. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLOS Med. 3(11), e466 (2006).
  MedlineGoogle Scholar